Optimizing Diabetes Management in Metabolic-Bariatric Surgery

The rising global prevalence of obesity and type 2 diabetes poses significant challenges to metabolic health. Metabolic-bariatric surgery has emerged as an effective intervention, offering not only weight loss but also the potential for type 2 diabetes remission and improved glycaemic control. The Joint British Diabetes Societies for Inpatient Care (JBDS-IP) has developed guidelines to optimize diabetes management for individuals undergoing this surgery, highlighting the need for a multidisciplinary approach and personalized treatment plans. Key recommendations from the guidelines include pre-operative glycaemic optimization, aiming for an HbA1c level below 69 mmol/mol (8.5%) when safe. This is crucial as elevated HbA1c levels are associated with increased risks of surgical complications. Furthermore, the guidelines stress the importance of preventing hypoglycaemia during all phases of care, particularly in patients on insulin or certain oral medications. For those with type 2 diabetes, the use of metformin, DPP4 inhibitors, and GLP-1 based therapies can continue during the liver reduction diet (LRD), while medications like sulfonylureas and SGLT2 inhibitors should be discontinued to minimize hypoglycaemia risks. Insulin doses should be reduced by 35%-50% during the LRD and adjusted post-operatively based on individual glycaemic control. For individuals with type 1 diabetes, it is critical to maintain insulin therapy to prevent diabetic ketoacidosis (DKA), necessitating careful planning with diabetes care teams. Post-operative care involves regular glucose monitoring and medication adjustments to ensure optimal glycaemic control. The guidelines serve as a comprehensive framework for clinicians, aiming to enhance inpatient diabetes care and improve outcomes for patients undergoing metabolic-bariatric surgery. Readers can apply these findings by discussing their diabetes management strategies with healthcare providers, especially if considering metabolic-bariatric surgery. Understanding the importance of glycaemic control and medication adjustments can empower individuals to make informed decisions about their health journey. Regular monitoring of biomarkers such as HbA1c and fasting glucose is essential to track progress and adjust treatment plans accordingly. The findings from this research connect to several key biomarkers relevant to metabolic health. HbA1c is a critical marker for long-term glycaemic control, while fasting insulin and glucose levels provide insight into insulin resistance and overall metabolic function. Monitoring these biomarkers can help individuals assess their risk for complications and guide dietary and lifestyle changes. In conclusion, optimizing diabetes management in the context of metabolic-bariatric surgery is vital for improving patient outcomes. By adhering to the guidelines and focusing on individualized care, healthcare providers can significantly enhance the quality of life for individuals with diabetes undergoing this transformative procedure.